KR102640198B1 - Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료 - Google Patents

Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료 Download PDF

Info

Publication number
KR102640198B1
KR102640198B1 KR1020177035838A KR20177035838A KR102640198B1 KR 102640198 B1 KR102640198 B1 KR 102640198B1 KR 1020177035838 A KR1020177035838 A KR 1020177035838A KR 20177035838 A KR20177035838 A KR 20177035838A KR 102640198 B1 KR102640198 B1 KR 102640198B1
Authority
KR
South Korea
Prior art keywords
subject
certain embodiments
actriib
delete delete
signaling inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177035838A
Other languages
English (en)
Korean (ko)
Other versions
KR20180006437A (ko
Inventor
케네스 엠. 아티에
아브데라만 라아뎀
라제쉬 쵸프라
제이 백스트롬
Original Assignee
셀진 코포레이션
악셀레론 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션, 악셀레론 파마 인코포레이티드 filed Critical 셀진 코포레이션
Publication of KR20180006437A publication Critical patent/KR20180006437A/ko
Application granted granted Critical
Publication of KR102640198B1 publication Critical patent/KR102640198B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177035838A 2015-05-13 2016-05-12 Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료 Active KR102640198B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US62/161,136 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US62/173,836 2015-06-10
US201562243457P 2015-10-19 2015-10-19
US62/243,457 2015-10-19
PCT/US2016/031999 WO2016183280A1 (en) 2015-05-13 2016-05-12 Treatment of beta-thalassemia using actrii ligand traps

Publications (2)

Publication Number Publication Date
KR20180006437A KR20180006437A (ko) 2018-01-17
KR102640198B1 true KR102640198B1 (ko) 2024-02-23

Family

ID=57248528

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035838A Active KR102640198B1 (ko) 2015-05-13 2016-05-12 Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료

Country Status (15)

Country Link
US (1) US20180125928A1 (enExample)
EP (1) EP3294320A4 (enExample)
JP (2) JP6976859B2 (enExample)
KR (1) KR102640198B1 (enExample)
CN (1) CN107847562A (enExample)
AU (2) AU2016261913B2 (enExample)
CA (1) CA2985777A1 (enExample)
HK (1) HK1251157A1 (enExample)
IL (2) IL284686B2 (enExample)
JO (1) JOP20160092B1 (enExample)
MY (1) MY189601A (enExample)
PH (1) PH12017502079A1 (enExample)
TN (1) TN2017000468A1 (enExample)
TW (2) TWI762444B (enExample)
WO (1) WO2016183280A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00380B (me) 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
DK3227675T3 (da) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
CN108350057A (zh) 2015-05-20 2018-07-31 细胞基因公司 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
SMT202400437T1 (it) * 2017-06-14 2024-11-15 Celgene Corp Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
EP3788065B1 (en) 2018-04-30 2025-08-27 The Children's Hospital Of Philadelphia Improving anemias by combining agents
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
KR20210088548A (ko) * 2018-10-31 2021-07-14 셀진 코포레이션 액티빈-actrii 리간드 트랩을 사용하는 고리 철적혈모구가 있는 대상체에서 매우 낮은, 낮은 또는 중간 위험 골수이형성 증후군으로 인한 빈혈의 치료
MX2022000782A (es) 2019-07-19 2022-04-18 Vifor Int Ag Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
MX2022012610A (es) * 2020-04-13 2022-11-07 Celgene Corp Metodos para tratar anemia usando una trampa de ligando de receptor de activina de tipo iib (actriib) y fedratinib.
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4240399A4 (en) * 2020-11-06 2024-10-09 Acceleron Pharma Inc. FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS
US20240181007A1 (en) * 2021-01-08 2024-06-06 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR20230134476A (ko) 2021-01-20 2023-09-21 비포르 (인터내셔날) 아게 골수이형성 증후군(mds)의 치료에 사용하기 위한 페로포틴-억제제
AU2024310149A1 (en) 2023-06-26 2025-11-20 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2025122830A1 (en) * 2023-12-08 2025-06-12 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
KR101871510B1 (ko) * 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
LT3750552T (lt) * 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
ES2613523T3 (es) * 2009-09-09 2017-05-24 Acceleron Pharma, Inc. Antagonistas de ActRIIb y dosificación y usos de los mismos
EP3520805B1 (en) * 2011-10-17 2021-03-10 Acceleron Pharma Inc. Compositions for treating myelofibrosis
AU2013240306A1 (en) * 2012-03-30 2014-10-09 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate- 2-sulfatase
JP6401172B2 (ja) * 2012-10-24 2018-10-10 セルジーン コーポレイション 貧血の治療方法
CA2889209C (en) * 2012-10-24 2023-08-22 Celgene Corporation Biomarker for use in treating anemia
PT2925864T (pt) * 2012-11-27 2019-02-06 Childrens Medical Ct Corp Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal

Also Published As

Publication number Publication date
WO2016183280A1 (en) 2016-11-17
IL284686A (en) 2021-08-31
TW201709927A (zh) 2017-03-16
TWI814187B (zh) 2023-09-01
NZ737043A (en) 2025-02-28
AU2021258087B2 (en) 2023-04-27
JP2018520094A (ja) 2018-07-26
EP3294320A1 (en) 2018-03-21
IL255527B (en) 2021-07-29
JOP20160092B1 (ar) 2023-03-28
HK1251157A1 (zh) 2019-01-25
US20180125928A1 (en) 2018-05-10
AU2021258087A1 (en) 2021-11-25
JP2021191755A (ja) 2021-12-16
CN107847562A (zh) 2018-03-27
TW202231294A (zh) 2022-08-16
TN2017000468A1 (en) 2019-04-12
IL284686B (en) 2023-01-01
TWI762444B (zh) 2022-05-01
AU2016261913B2 (en) 2021-08-12
IL284686B2 (en) 2023-05-01
PH12017502079A1 (en) 2018-06-11
JP6976859B2 (ja) 2021-12-08
IL255527A (en) 2018-01-31
CA2985777A1 (en) 2016-11-17
AU2016261913A1 (en) 2017-11-30
EP3294320A4 (en) 2018-12-26
KR20180006437A (ko) 2018-01-17
MY189601A (en) 2022-02-18

Similar Documents

Publication Publication Date Title
AU2021258087B2 (en) Treatment of beta-thalassemia using ActRII ligand traps
AU2021212084B2 (en) Activin-ActRII antagonists and uses for treating anemia
US20230293634A1 (en) Activin-actrii antagonists and uses for treating bone and other disorders
CN111050770A (zh) 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
CN113604550A (zh) 用于治疗贫血症的生物标志物
HK1248807B (zh) 激活素-actrii拮抗剂及用於治疗贫血症的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210511

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230414

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230911

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230414

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230911

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230601

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210511

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240119

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20231211

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230911

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230601

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210511

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240220

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240221

End annual number: 3

Start annual number: 1

PG1601 Publication of registration